多奈哌齐
医学
心力衰竭
内科学
亚临床感染
心脏病学
痴呆
脑利钠肽
疾病
作者
Toru Kubo,Takayuki Sato,Tatsuya Nakatani,Hiroaki Kitaoka,Fumiyasu Yamasaki,Naoto Kamimura,Shinji Shimodera,Tatsuo Iiyama,Naoya Kumagai,Yoshihiko Kakinuma,André Diedrich,Jens Jordan,David Robertson,Yoshinori Doi
出处
期刊:Journal of Cardiovascular Pharmacology
[Ovid Technologies (Wolters Kluwer)]
日期:2012-09-01
卷期号:60 (3): 310-314
被引量:36
标识
DOI:10.1097/fjc.0b013e3182609a74
摘要
To study prospectively influences of donepezil, an acetylcholinesterase inhibitor against Alzheimer disease, on cardiovascular system, we evaluated cardiovascular changes occurring during new initialized treatment with donepezil in 49 dementia patients over 6 months. No patient suffered from cardiovascular events. In clinical changes between baseline and the first evaluation after donepezil treatment, heart rate and plasma brain natriuretic peptide (BNP) levels as a marker for heart failure did not change (BNP: 59.62 ± 62.71 pg/mL at baseline to 53.18 ± 42.34 pg/mL at first evaluation; P = 0.262). We further examined plasma BNP levels in 2 groups into which the patients were divided at baseline according to the cut-off plasma BNP level of 60 pg/mL. In patients with high level of BNP, the BNP levels decreased after administration of donepezil (116.39 ± 76.58 pg/mL at baseline to 82.24 ± 46.64 pg/mL at first evaluation; P = 0.011) with the tendency to be reduced in the follow-up period. BNP did not change in patients with low level of BNP. Donepezil seemed to be safe in patients with dementia without symptomatic heart disease and significantly decreased plasma BNP levels in patients with subclinical chronic heart failure.
科研通智能强力驱动
Strongly Powered by AbleSci AI